Compliance is moving from paperwork to proof of execution. Pharmaceutical compliance frameworks rely on documented evidence. Laboratories record scientific activities, review generated records, and provide regulators with evidence that approved processes have been followed. Documentation serves as a primary mechanism for demonstrating process adherence and maintaining quality control.

That model is increasingly being challenged. At the same time, pharmaceutical companies are investing heavily in digitalisation and artificial intelligence. The two developments are more closely connected than they may appear: the systems that make compliance more reliable can also create the structured data and consistent processes that AI requires.

As scientific processes become more complex, regulators and industry leaders are moving towards a different idea: compliance should be demonstrated not only by what organisations record, but by how work is carried out. This approach, known as “review by exception”, shifts the focus from checking every activity retrospectively to identifying and addressing deviations from the expected process. The aim is for systems to make the correct action the natural outcome, support compliance by design and minimise routine manual review. Instead, Quality Assurance (QA) can focus its attention on exceptions that require investigation or intervention. The future of compliance is therefore less about reconstructing events after they happen and more about designing systems in which compliant behaviour is the natural outcome.

This is a difficult transition. Regulation has always evolved carefully, and rightly so. Patient safety cannot be compromised by rapid change. But the slow evolution of standards and regulatory expectations can create an unintended burden: organisations often build new digital capabilities on top of old processes, creating a mixture of modern technology and outdated workflows.

Deloitte’s 2025 Global Life Sciences Outlook highlights the scale of this transformation. Their research surveyed 150 C-suite executives across pharmaceutical, biotechnology and medical technology companies in North America, Europe, and Asia. It found that 68% of executives expected revenue growth, and 57% expected margin expansion. Around 60% identified digital transformation or generative artificial intelligence as one of the most significant trends shaping their businesses, while nearly 60% planned to increase investment in generative AI across the value chain.

Deloitte estimates that AI investments could generate up to 11% of revenue value across functional areas over the next five years. The challenge is whether organisations are building the foundations needed to achieve it.

Artificial intelligence receives much of the attention, but AI does not create value from incomplete processes. It depends on structured data, reliable workflows and consistentexecution. Many organisations are investing in advanced technologies while still relying on fragmented systems, manual transfers and inconsistent laboratory practices.

In regulated laboratory environments, those foundations begin with compliance and data integrity; in non-GxP environments, the emphasis can be more heavily weighted towards flexibility and experimentation.

The question is therefore not simply whether companies are adopting AI. It is whether their laboratories are ready for it.

Digital standardisation is becoming a strategic capability

Digital standardisation is becoming less a question of technical efficiency than of how organisations create a common foundation across laboratories, systems and sites.

For pharmaceutical companies operating across multiple sites, countries and scientific disciplines, standardisation affects far more than operational efficiency. It influencesprocurement decisions, system integration, maintenance strategies and the ability to scale innovation.

A laboratory that uses standardised instruments, connected systems and consistent workflows can adopt new technologies more effectively. A laboratory built around isolatedsolutions creates long-term complexity.

The balance is different across laboratory environments. In GxP settings, standardisation and controlled execution are central to demonstrating compliance. In non-GxP research environments, scientists may require greater flexibility to adapt methods and workflows. Digitalisation therefore should not mean imposing identical controls everywhere, butestablishing the appropriate level of standardisation for each environment.

This is increasingly important as organisations evaluate new vendors and technologies. The question is no longer simply whether a system performs a specific task. It is whether it can connect with the wider digital ecosystem.

Compliance by design: making data integrity part of the process

Regulatory requirements place data integrity at the centre of laboratory processes, with organisations expected to maintain accurate, reliable, and traceable records.

The FDA’s guidance on Data Integrity and Compliance with Drug CGMP reinforces the importance of ALCOA+ principles: data must be attributable, legible, contemporaneous, original and accurate, alongside being complete, consistent, enduring and available.

The implication is significant: data integrity cannot rely solely on final review. It is maintained through controls embedded within routine laboratory operations.

Digital laboratory systems capture information that records who performed an action, what was changed, when the change occurred, why it was made, and where the information originated.

Data integrity frameworks use traceability to document the history of data changes. When a scientist changes a value, the system records the reason for the change, the original value, and the updated value. This is not simply a regulatory requirement. It is the foundation of trust. In GxP environments, that trust is essential to demonstrating compliance. In digital laboratories more broadly, the same traceability can also make data more useful for analysis and automation.

Organisations continue to implement this model. Electronic signatures, audit trails, and connected systems are in use, but their implementation varies across laboratory environments and may not always provide a complete compliance framework.

The industry is moving towards a future where systems themselves provide evidence of correct execution, rather than requiring organisations to reconstruct evidence afterwards. Standards such as LADS (Laboratory and Analytical Device Standard), based on OPC UA, and SiLA 2, developed by the SiLA Consortium, are helping to address this challenge. By providing common ways for instruments and software to communicate, they reduce the reliance on bespoke connections between systems. For laboratories, digitalisation is therefore not simply about connecting equipment; it is about creating the infrastructure needed to make quality and compliance part of everyday operations; and to make the resulting data more usable.

The challenge of global consistency

Pharmaceutical organisations may operate laboratories across multiple locations and jurisdictions. Consistent scientific processes across these environments depend on aligned procedures, systems, and data practices.

Local requirements, established practices and regional preferences can make harmonisation difficult. A process that works well in one location may not immediately translate to another.

The solution is not to remove local expertise. Instead, organisations need to identify which elements must be standardised and which areas require flexibility. The strongest models combine global standards with local execution knowledge, rather than treating standardisation as uniformity.

Another challenge is communication. Laboratories may use different terminology and working methods across locations. Differences between scientific and corporate language, together with variations in documentation practices, can influence how information is interpreted.

As pharmaceutical companies become more international, standardisation becomes a tool not only for efficiency, but for reducing misunderstanding.

Compliance as a driver of performance

Compliance and scientific work address different aspects of laboratory operations. Scientists need processes that support reliable results and, particularly in non-GxP research, allow experimentation. Compliance functions need processes that provide control, traceability and evidence of adherence to approved procedures.

But the future of compliance should be different.

When designed correctly, compliance creates structured information that can be reused, analysed and improved. It provides a foundation for operational excellence rather thanacting as a restriction.

The question is not whether compliance creates additional work. The question is whether organisations design processes in a way that removes unnecessary work.

A well-designed digital workflow should make the compliant path the easiest path.

ISPE’s Pharma 4.0 maturity model reflects this idea. The framework describes a progression from basic digitalisation towards fully integrated intelligent operations. It argues that organisations cannot achieve advanced automation, artificial intelligence, or autonomous operations without first establishing standardised processes, digital workflows, reliable data, and connected systems.

This raises an uncomfortable question for many organisations: are they attempting to implement AI before they have solved the fundamentals?

AI needs a foundation of standardised data

Artificial intelligence is attracting enormous attention across life sciences. The promise is substantial: faster research, improved decision-making and more efficient operations.

But AI is only as valuable as the data it receives.

A single data point without context has limited meaning. A measurement of five grams may appear precise, but without knowing the instrument, conditions, operator, method and purpose, it has limited meaning.

AI requires context.

Organisations face challenges when historical data is created through inconsistent processes, varying terminology, and disconnected systems. The information may exist, but its structure can limit analysis and interpretation.

Companies that want to benefit from AI must begin by improving how data is created today. Building the right foundations now is far easier than attempting to reverse-engineer decades of inconsistent information later.

The next generation of regulatory expectations

Digitally mature laboratories are expected to operate within regulatory frameworks that continue to build on existing principles rather than introduce entirely new expectations.

What will change is how those expectations are achieved.

Digital maturity will increasingly give organisations new ways to demonstrate compliance through connected systems rather than relying primarily on extensive manual documentation. Instead of requesting printed records and reconstructed evidence, they will expect access to reliable digital processes that provide transparency by design.

The bigger question will be the role of artificial intelligence itself.

How are AI systems validated when they continuously evolve? How do organisations demonstrate that AI-driven decisions remain reliable and explainable? How will regulators evaluate technologies that do not always produce identical outputs?

These questions remain difficult. But the direction is becoming clearer. The laboratory of the future will not be defined by how much documentation it creates. It will be defined by how effectively its digital systemscreate trust.

Digital standardisation is therefore not simply an efficiency project. It is becoming the foundation for compliance, productivity and scientific innovation.

Learn more: https://laboperator.com/contact